Acute myeloid leukemia (AML) can be grouped into morphologically or genetically defined subtypes. Today, the AML phenotype-genotype associations, that is, FAB/WHO (French-American-British/World Health Organization) definitions and recurrent molecular mutations, are not fully understood. Therefore, we evaluated the impact of molecular mutations on the AML differentiation stage by molecular profiling of 4373 adult de novo AML patients in 7 cytomorphological subtypes. We investigated mutations in 20 genes, including myeloid transcription factors (CEBPA, RUNX1), tumor suppressors (TP53, WT1), DNA modifiers (DNMT3A, IDH1/2, TET2), chromatin modifiers (ASXL1, MLL), signal transduction genes (FLT3, KRAS, NRAS) and NPM1. The most frequently mutated genes per cytomorphological subtype were RUNX1 in M0 (43%), NPM1 in M1 (42%), DNMT3A in M2 (26%), NPM1 in M4 (57%), M5a (49%) and M5b (70%) and TP53 in M6 (36%). Although some gene mutations were frequent in several cytomorphological subtypes, a series of associations of co-occurring mutations with distinct phenotypes were identified for molecularly defined subcohorts. FLT3, NPM1 and WT1 mutations were associated with an immature phenotype in myeloblastic AML, whereas other combinations involving ASXL1, RUNX1, MLL-PTD, CEBPA or KRAS were more frequent in myeloblastic AML with maturation. Within the NPM1 mutated subcohort, ASXL1 mutations were significantly associated with a monoblastic differentiation and DNMT3A mutations with a monocytic phenotype.

MLL Munich Leukemia Laboratory Munich Germany

MLL2 s r o Prague Czech Republic

Zobrazit více v PubMed

Leukemia. 2008 May;22(5):915-31 PubMed

Blood. 2008 Mar 1;111(5):2527-37 PubMed

Blood. 2006 May 15;107(10):3847-53 PubMed

Leukemia. 2013 Jan;27(1):82-91 PubMed

Best Pract Res Clin Haematol. 2010 Sep;23(3):379-90 PubMed

Haematologica. 2005 Jul;90(7):881-9 PubMed

Blood. 2004 Nov 15;104(10):3078-85 PubMed

Blood. 2009 Oct 1;114(14):3024-32 PubMed

Br J Haematol. 1976 Aug;33(4):451-8 PubMed

Genes Chromosomes Cancer. 2007 May;46(5):494-9 PubMed

N Engl J Med. 1983 Sep 15;309(11):630-6 PubMed

Blood. 2011 Feb 24;117(8):2348-57 PubMed

Ann Intern Med. 1985 Oct;103(4):620-5 PubMed

Genes Chromosomes Cancer. 1992 Jul;5(1):57-66 PubMed

Leukemia. 2012 May;26(5):934-42 PubMed

Leukemia. 2010 May;24(5):1065-9 PubMed

J Clin Oncol. 2010 Aug 20;28(24):3858-65 PubMed

Leukemia. 2015 Mar;29(3):660-7 PubMed

Leukemia. 2002 Jan;16(1):53-9 PubMed

Protein Sci. 2013 May;22(5):545-56 PubMed

Blood. 2003 Oct 1;102(7):2395-402 PubMed

Haematologica. 2007 Apr;92(4):519-32 PubMed

Haematologica. 2008 Feb;93(2):283-6 PubMed

Neoplasia. 2014 Jun;16(6):481-8 PubMed

Leukemia. 2014 Aug;28(8):1586-95 PubMed

Leukemia. 2014 Apr;28(4):794-803 PubMed

N Engl J Med. 2013 May 30;368(22):2059-74 PubMed

Blood. 2005 Dec 1;106(12):3733-9 PubMed

N Engl J Med. 2012 Mar 22;366(12):1079-89 PubMed

Blood. 2010 Dec 16;116(25):5486-96 PubMed

Br J Haematol. 2002 Aug;118(2):426-31 PubMed

Curr Oncol Rep. 2002 Sep;4(5):390-7 PubMed

Genes Chromosomes Cancer. 2002 Sep;35(1):20-9 PubMed

Leukemia. 2013 Jul;27(7):1573-8 PubMed

Leukemia. 2011 Aug;25(8):1297-304 PubMed

Leukemia. 1989 Jan;3(1):42-7 PubMed

Leuk Lymphoma. 2014 Aug;55(8):1725-34 PubMed

Leukemia. 2013 Sep;27(9):1940-3 PubMed

N Engl J Med. 2008 May 1;358(18):1909-18 PubMed

Leukemia. 2006 Feb;20(2):368-71 PubMed

Blood. 2012 Oct 11;120(15):2963-72 PubMed

Blood. 2011 Nov 17;118(20):5593-603 PubMed

N Engl J Med. 2005 Jan 20;352(3):254-66 PubMed

Blood. 2002 Jul 1;100(1):59-66 PubMed